- Home
- DAWN vs TILE Comparison
DAWN vs TILE Comparison
Compare DAWN & TILE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- TILE
- Stock Information
- Founded
- DAWN 2018
- TILE 1973
- Country
- DAWN United States
- TILE United States
- Employees
- DAWN N/A
- TILE N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- TILE Home Furnishings
- Sector
- DAWN Health Care
- TILE Consumer Discretionary
- Exchange
- DAWN Nasdaq
- TILE Nasdaq
- Market Cap
- DAWN 1.3B
- TILE 1.5B
- IPO Year
- DAWN 2021
- TILE N/A
- Fundamental
- Price
- DAWN $12.24
- TILE $24.71
- Analyst Decision
- DAWN Strong Buy
- TILE Buy
- Analyst Count
- DAWN 7
- TILE 2
- Target Price
- DAWN $36.33
- TILE $22.00
- AVG Volume (30 Days)
- DAWN 1.1M
- TILE 512.9K
- Earning Date
- DAWN 02-24-2025
- TILE 02-25-2025
- Dividend Yield
- DAWN N/A
- TILE 0.16%
- EPS Growth
- DAWN N/A
- TILE 11277.07
- EPS
- DAWN N/A
- TILE 1.44
- Revenue
- DAWN $101,953,000.00
- TILE $1,305,766,000.00
- Revenue This Year
- DAWN N/A
- TILE $6.86
- Revenue Next Year
- DAWN $35.22
- TILE $3.56
- P/E Ratio
- DAWN N/A
- TILE $17.26
- Revenue Growth
- DAWN N/A
- TILE 2.66
- 52 Week Low
- DAWN $11.13
- TILE $12.02
- 52 Week High
- DAWN $18.07
- TILE $27.34
- Technical
- Relative Strength Index (RSI)
- DAWN 45.74
- TILE 54.06
- Support Level
- DAWN $11.13
- TILE $23.82
- Resistance Level
- DAWN $12.74
- TILE $24.34
- Average True Range (ATR)
- DAWN 0.51
- TILE 0.65
- MACD
- DAWN 0.06
- TILE 0.05
- Stochastic Oscillator
- DAWN 51.15
- TILE 92.53
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About TILE Interface Inc.
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments - AMS and EAAA.